



i3 ACQUIRES CANREG

Acquisition Creates One of the Most Comprehensive Regulatory Affairs Consulting Firms in the World

December 9, 2009 – Global pharmaceutical services company i3 has acquired CanReg, Inc., a global regulatory consulting firm that assists pharmaceutical, biotechnology, and medical device and diagnostics clients at all stages of regulatory approval, and provides unique customized guidance, education and training to companies of all sizes. CanReg and i3 have worked together on a number of important projects over the years and have recognized the unique value each company brought to those customer engagements.

CanReg has successfully helped customers navigate the regulatory process to bring more than 500 distinct products to market in more than 60 countries. With this acquisition, i3 is now able to offer its customers enhanced international regulatory submission and approval process consulting.

The new business, now operating as i3 CanReg, creates one of the most comprehensive regulatory affairs consulting firms in the world. i3 customers will benefit by gaining direct access to broad clinical and risk management expertise, as well as a variety of other services to move their products through the development and commercialization regulatory lifecycles.

The CanReg executive team, led by Anne Tomalin, president, will continue in their roles with i3 CanReg. CanReg's senior leadership is dedicated to maintaining strong relationships with customers and regulators, and will continue to develop its business as part of i3.

For more information about CanReg, please visit www.canreginc.com.